GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crism Therapeutics Corp (LSE:CRTX) » Definitions » PB Ratio

Crism Therapeutics (LSE:CRTX) PB Ratio : 1.51 (As of Apr. 22, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Crism Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-22), Crism Therapeutics's share price is £0.095. Crism Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 was £0.06. Hence, Crism Therapeutics's PB Ratio of today is 1.51.

The historical rank and industry rank for Crism Therapeutics's PB Ratio or its related term are showing as below:

LSE:CRTX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.51
Current: 1.51

During the past 13 years, Crism Therapeutics's highest PB Ratio was 1.51. The lowest was 0.00. And the median was 0.00.

LSE:CRTX's PB Ratio is ranked better than
62.77% of 1284 companies
in the Biotechnology industry
Industry Median: 2.12 vs LSE:CRTX: 1.51

During the past 12 months, Crism Therapeutics's average Book Value Per Share Growth Rate was -84.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -48.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -32.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -17.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Crism Therapeutics was 2.60% per year. The lowest was -48.10% per year. And the median was -10.50% per year.

Back to Basics: PB Ratio


Crism Therapeutics PB Ratio Historical Data

The historical data trend for Crism Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crism Therapeutics PB Ratio Chart

Crism Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.96 1.05 0.61 0.39

Crism Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.61 0.87 0.39 0.83

Competitive Comparison of Crism Therapeutics's PB Ratio

For the Biotechnology subindustry, Crism Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crism Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crism Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Crism Therapeutics's PB Ratio falls into.


;
;

Crism Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Crism Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2024)
=0.095/0.063
=1.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Crism Therapeutics  (LSE:CRTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Crism Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Crism Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Crism Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Kingston Chambers, P.O. Box 173, Tortola, Road Town, VGB
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.

Crism Therapeutics Headlines

No Headlines